Clinical trial · Interventional
Flu-Bu-Mel Based Conditioning Regimen for Patients With Lymphoid Malignancies Undergoing Allo-HSCT
Phase II Clinical Trial of Flu-Bu-Mel-E (Fludarabine, Busulfan, Melphalan and Etoposide) as Conditioning Regimen for Patients With Lymphoid Malignancies Undergoing Allogeneic Stem Cell Transplantation
NCT04897139CI-TRIAL-00070792unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
In this phase II clinical trial, we evaluate the efficacy and feasibility of conditioning regimen of fludarabine 150mg/m2, busulfan 9.6mg/kg, melphalan 100mg/m2 and etoposide 800mg/m2 in patients with lymphoid malignancies.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoid Neoplasm | Lymphoid Neoplasm | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Flu-Bu-Mel-E | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- treatment arm
- description
- treatment arm
- interventionNames
- Drug: Flu-Bu-Mel-E
Primary outcomes (1)
- measure
- disease-free survival
- timeFrame
- 1 year after allo-HSCT
- description
- event defined as disease progression, relapse or death of any causes
Secondary outcomes (4)
- measure
- Overall survival
- timeFrame
- 1 year after allo-HSCT
- description
- event defined as death of any causes
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 16 Years
- Maximum age
- 60 Years
Show eligibility criteria text
Inclusion Criteria: * lymphoid malignancies * donor available: HLA matched sibling, unrelated donor or haplo-identical related donor. * patients with ECOG \<3 Exclusion Criteria: * inform consent not provided * ECOG \>=3 * poor liver function (enzyme \>2N or bilirubin \>2N) * poor renal function (Scr \>2N) * poor cardiac function (EF \<45%)
References
Publications (0)
Data not yet available
No reference posted for this study.